COVID-19 therapies: Eli Lilly begins clinical testing for Baricitinib, Anti-Ang2
by Press Release from Outbreak News Today on (#522T7)
Eli Lilly and Company announced Friday it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib as an arm in NIAID's Adaptive COVID-19 Treatment Trial. The study will investigate the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed ["]
The post COVID-19 therapies: Eli Lilly begins clinical testing for Baricitinib, Anti-Ang2 appeared first on Outbreak News Today.